focus -WSS

focus

author：explore 2025-09-28 00:51:27 - browse：65456

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Plane’s emergency slide plummets from sky, hits Chicago home

entertainment

WSS

The effects of a landmark ruling on DNA ownership are becoming clearer

Black vets could get higher VA benefits if race not used in lung test

GSK’s asthma push continues as drug succeeds in Phase 3 trials

HHS's proposed rule does nothing to address the climate crisis

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Brain technologies pose threats that are all too real, experts warn

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

AltruBio raises $225 million to develop ulcerative colitis drug

Dobbs anniversary: the lost opportunity of abortion as health care

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

DIEP, the 'gold standard' of breast reconstruction, is under threat

TikTok cracks down on users posting about weight loss drugs

Malaria cases in Florida and Texas: Here’s what you need to know

Primary care doctor shortage won't be solved by free med school tuition

Peter Hotez and the public health issue of online harassment

AI for drug discovery: Experts on separating hype from reality

focus

The effects of a landmark ruling on DNA ownership are becoming clearer

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Welsh Carson private equity firm escapes from FTC antitrust case

Resistance to cancer drugs: A new genetic explanation

Lawmakers grill UnitedHealth CEO on Change cyberattack

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

hotspot

entertainment

explore

Wikipedia